Could a flavonoid combo reverse liver scarring and prevent cancer in hepatitis b?
NCT ID NCT07084948
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed phase 4 trial tested whether adding SB Flavon (a blend of flavonoids, vitamin C, and L-arginine) to standard Tenofovir therapy can reverse advanced liver scarring (cirrhosis) and prevent liver cancer in 134 people with chronic hepatitis B. The study measured liver stiffness and cancer development over time. While the approach is promising, the results need confirmation in larger trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SB Flavon (a blend of flavonoids, ascorbic acid, and L-arginine) plus Tenofovir
- What this could lead to
- If successful, this combination could help reverse advanced liver scarring and lower the risk of liver cancer in people with chronic hepatitis B.
- What could go wrong
- This is a single completed phase 4 trial with 134 participants. The results may not apply to all patients, and the supplement-like nature of SB Flavon means larger, more rigorous studies are needed to confirm benefits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HBV-RELATED CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Saigon Biopharma Company Limited
Hồ Chí Minh, Ho Chi Minh City, 700000, Vietnam
-
Saigon Biopharma LLC
Wilmington, Delaware, 19801-6601, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a cancer vaccine prime the body to better fight liver tumors?
- Training the immune system to hunt down leftover liver cancer cells
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- Could a genetic marker guide future cancer therapies in taiwan?
- Can a tumor-zapping procedure also wake up the immune system?
- A machine that keeps donor livers alive outside the body — could it transform transplantation?